Articles tagged with Cancer Medication
Researchers at UCLA's Jonsson Cancer Center have discovered a novel anti-inflammatory cell signaling pathway that may serve as a vital Yin-Yang mechanism to maintain the delicate balance of immune response. This discovery may lead to new ways to fight cancer and inflammatory diseases.
A special publication from the University of Rochester Medical Center aims to improve understanding and management of cancer-related fatigue. Studies show that exercise and support groups are effective in helping people cope with this challenging side effect.
Two research teams developed models to predict NSCLC patient outcomes based on protein patterns. The new models, validated in independent groups, could help physicians decide treatment options for patients with NSCLC. Researchers identified a 25-signature proteomic signature associated with increased survival among NSCLC patients.
A review of nine randomized trials shows that patients treated with cisplatin lived slightly longer than those treated with carboplatin, with a median survival of 9.1 months compared to 8.4 months. However, the difference in survival was not statistically significant for all patient groups.
Northeastern University researchers have discovered a novel method for studying the DNA binding of small molecules, which may aid in rational drug design targeting cancer and other diseases. The team used single DNA molecule stretching to investigate ethidium and ruthenium complexes, achieving unprecedented detail.
A University of Michigan study found that 86% of patients with follicular lymphoma survived after 8 years of treatment with Bexxar, a radioimmunotherapy drug. This success rate compares favorably to state-of-the-art chemotherapy regimens, making Bexxar an attractive option for patients.
Researchers at Mayo Clinic have discovered that low doses of gabapentin substantially reduce hot flashes in patients undergoing anti-hormonal treatment for prostate cancer. The study found that gabapentin reduced the frequency and intensity of hot flashes by up to 46% in men receiving androgen deprivation therapy.
A small group of Rochester breast cancer survivors experienced major improvements in memory, concentration and learning after taking modafinil for eight weeks. The study suggests the drug could provide relief to those suffering from 'chemo-brain', a persistent side effect of chemotherapy.
Michael R. Zalutsky received the award for his significant contributions to medical science, especially in using molecular targeting to combat cancer. His research has had a substantial impact on therapeutic nuclear medicine and its applications.
Researchers have discovered six new antitumor compounds that are more effective against cancerous cells while minimizing harm to healthy cells. The study, conducted at the University of Granada, uses a new technique called Microarrays to identify the effects of drugs on genes.
Almac Diagnostics plans to develop and clear its In Vitro Diagnostic for colorectal cancer using the 510(k) approach, accelerating regulatory submission. The company's prognostic gene signature was developed from FFPE samples and aims to help clinicians determine cancer recurrence risk in stage II CRC patients.
A phase III clinical study shows temsirolimus improves overall survival in patients with advanced renal cell carcinoma compared to standard treatment interferon. The treatment was also better tolerated, with fewer severe side effects.
A comprehensive study found that 85% of pediatric chemotherapy errors reached patients, with most common mistakes involving improper dosing and timing. The antimetabolite class of chemotherapeutic agents was most frequently associated with errors, highlighting the need for targeted medication administration safeguards.
Scientists developed a new mouse model that closely mimics human cancers, enabling researchers to identify cancer-causing genes and improve laboratory drug testing. The model's genetic instability was found to be similar to that in human tumors, suggesting its potential for guiding gene discovery.
A colon cancer researcher outlines the benefits of aspirin in preventing colon cancer in high-risk individuals. Dr. Sanford Markowitz' editorial provides a roadmap for how medical science should employ aspirin and new aspirin-like drugs to decrease the risk of developing colon cancer.
New guidelines provide a rational treatment approach for managing skin reactions caused by Epidermal Growth Factor Receptor Inhibitors (EGFRIs), which are used to treat various types of cancer. The recommended treatment involves using moisturizers, protecting against sunlight, and targeted medications to manage the severity of the rash.
A subset of endometrial cancers has been found to have previously unrecognized alterations in the FGFR2 gene, resulting in uncontrolled cell division. This discovery could accelerate the development of new treatments for endometrial cancer by targeting drugs already in clinical trials.
Researchers have developed a nanocomposite particle that can target and destroy melanoma cancer cells using laser irradiation. The technology utilizes selectively absorbing metallic clusters to enhance light absorption within labeled cells, causing damage without affecting surrounding tissue.
Two UI studies show that the NSAID celecoxib has potent anticancer activity, killing head and neck cancer cells in the S phase of the cell cycle. This finding suggests that combining celecoxib with chemotherapies may provide better tumor control than radiation alone.
UC patients report a heavy psychological toll, with 82% experiencing increased stress and 62% feeling depressed. Nearly four out of five patients worry about long-term health effects, such as colon cancer or surgery. Non-compliance with medication is also a challenge, affecting up to half of patients.
Reolysin works synergistically with standard anti-cancer drugs, providing stronger responses than either agent alone. It also primes patients' immune systems against their particular cancer, leading to additional cancer cell killing and long-term remissions.
A report by European Society for Medical Oncology reveals stark inequalities in access to cancer treatment globally. Key findings include that Austria, France, and the US have high uptake of new cancer drugs, while countries like New Zealand, Poland, and South Africa have low uptake.
Researchers found that combining a diabetes drug with platinum-based chemotherapy boosted its potency in various cancer cell lines and mouse tumors. The combination halted or shrunk tumors up to three times more effectively than either drug alone.
A new study finds that the re-engineered Gleevec variant WBZ-7 is effective against both drug-resistant and nonresistant gastrointestinal cancer cells. The wrapping prototype seals out water molecules from a critical area, preventing resistance to the drug, and demonstrates promising results in laboratory studies.
Researchers found that chronic myeloid leukemia stem cells have a high frequency of BCR-ABL gene mutations, even in the absence of imatinib, which could lead to drug resistance. This genetic instability may contribute to relapses and disease progression.
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease (COPD) in a large trial. The study suggests that other mediators may be necessary to cause COPD, and raises concerns about the safety of the drug.
Researchers from Duke University found that generic biologics are unlikely to be significantly cheaper than brand-name versions due to higher manufacturing and marketing costs. The unique characteristics of biologics make them harder to replicate, resulting in lower price competition.
Researchers discovered a new way lung tumors become resistant to targeted therapy drugs like Iressa and Tarceva, involving the activation of an oncogene that bypasses blocked growth signal. A potential new treatment strategy using combination therapy against both protein targets is suggested for patients with resistant tumors.
The Phase III efficacy clinical trial showed statistically significant improvement on the primary efficacy endpoint at 30 minutes compared to placebo, indicating a greater reduction in pain. Patients treated with BEMA Fentanyl also demonstrated well-tolerated treatment with no reported drug-related changes to the oral mucosa.
The study found that lung cancer cells can become resistant to novel targeted agents by undergoing a miniscule molecular change in the EGFR protein. Researchers developed compounds to overcome resistance with innovative combinations of medications, which showed promise in preventing further resistance.
A new study suggests that targeting the survival protein Mcl1 may be an effective way to treat leukemia, particularly when combined with existing drugs like rituximab. The research found that knocking out Mcl1 can cause cancer cells to die, and combining it with rituximab killed significantly more leukemia cells than the drug alone.
Researchers found that the androgen receptor plays a key role in bladder cancer development, which explains why it affects men more than women. The discovery opens doors to new treatment options and may help doctors predict tumor recurrence.
Researchers at MGH Cancer Center have discovered a molecular pathway underlying sensitivity to cisplatin in triple-negative breast cancers. The study found that p63 and p73 expression levels can predict cisplatin therapy effectiveness, leading to the design of a clinical trial for patients with advanced triple-negative breast cancer.
Triple-negative breast cancer cells are sensitive to cisplatin due to increased expression of delta-Np63 and TAp73 proteins. Cisplatin releases TAp73 from delta-Np63, leading to cell death. This study suggests using cisplatin as an early treatment option for individuals with triple-negative breast cancer.
Researchers have found that the novel targeted therapy NPI-0052 effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins. This approach has shown greater efficacy than its predecessor bortezomib when combined with other agents.
Researchers have identified gene expression signatures that can predict how individuals will respond to certain breast cancer drugs. These biomarkers could aid in tailoring treatments for women and identifying similar biomarkers for other types of cancer. A 'systems' approach suggests prioritizing experimental medicines for specific ca...
A study found that nearly a third of cancer patients take at least one medication that can cause serious harm or interact with other medications, including anticancer treatments. The most common interactions involve warfarin and anticonvulsants, posing significant risks to patients with brain tumors.
A novel cell culture technique could lead to the discovery of new drugs for preventing DCIS recurrence or progression. Breast cancer cells expressing a shortened form of the HER2 gene can be treated with lapatinib, but are resistant to trastuzumab.
The AACR-FDA-NCI Cancer Biomarkers Collaborative aims to integrate predictive biomarkers into clinical trials, addressing the translation of cancer knowledge into medical practice. The collaborative will develop guidelines for biomarker validation, informing policies as part of the FDA's Critical Path Initiative.
A phase III trial of 1,298 patients found that a combination of cetuximab and irinotecan increased progression-free survival over irinotecan alone. The treatment also showed a higher tumor response rate.
Researchers at Virginia Commonwealth University Massey Cancer Center have induced cell death in leukemia cells using a combination of bortezomib and romidepsin or belinostat. The findings suggest potentiated lethality and additive effects in human CLL cells.
A new protein-targeted drug, MCP110, has been found to have a synergistic effect when combined with current chemotherapy drugs like taxanes and vinca-alkaloid compounds. This combination improves the efficacy of systemic treatment for human lung and colon cancer cells.
Researchers discovered that an investigational cancer drug selectively kills cancer cells due to its affinity for a modified version of heat shock protein 90. The modification, called acetylation, allows the drug to target and block the activity of this protein, promoting cell survival.
Researchers found that patients who received Gleevec after surgery were significantly less likely to have cancer recurrence compared to those who didn't receive it. The study showed a 97% survival rate for patients on Gleevec, with only mild side effects reported.
The American Association for Cancer Research will present the AACR Distinguished Service Award and the AACR Public Service Award to Dr. Andrew C. von Eschenbach, Dr. Harold P. Freeman, and Dr. LaSalle D. Leffall, Jr., recognizing their outstanding contributions to leadership, education, and advocacy in cancer research. The awards will ...
A Princeton University-led research team has developed nanoparticles that can deliver medicine deep into the lungs or infiltrate cancer cells while leaving normal ones alone. The particles are too large to pass through normal cells but can target rapidly growing solid tumors and remain in the lungs, maximizing the effectiveness of inha...
Researchers at Jefferson University identified a protein called Akt1 that plays a crucial role in helping breast cancer cells spread. The finding could lead to the development of new drugs targeting this protein, potentially slowing or stopping the growth and progression of breast cancer.
Scientists have found a new approach to treating human cancers by understanding how a plant hormone, auxin, interacts with its receptor, TIR1. This discovery may lead to the development of new cancer drugs by targeting ubiquitin ligases, which are involved in various human diseases.
A new study from UCSD reveals that California's tobacco control program has led to a significant increase in smoking cessation rates, especially among young adults. Cessation rates have risen by 50% among those aged 20-34, while daily cigarette consumption has declined, particularly among older smokers.
Scientists have identified a natural mechanism by which tumors and viruses evade the immune response, leading to the development of new cancer therapies. By inhibiting an enzyme called IDO, researchers hope to restore the immune system's ability to target cancer cells. Early clinical trials are underway to test this approach.
Researchers at the University of Guadalajara have developed a natural drug carrier derived from tequila that shows promise in targeting colon diseases. The microspheres, made from fructans, can protect drugs from stomach acid and improve their effectiveness.
Research at St. Jude Children's Research Hospital shows that leukemic cells receive a protective niche from bone marrow mesenchymal cells, which release the amino acid asparagine to help them survive treatment with asparaginase. This finding suggests new strategies for enhancing anti-leukemic drugs and reducing leukemia recurrence rates.
A study on rheumatoid arthritis found that flexible use of drugs with close patient follow-up can effectively control the disease. Additionally, a trial on men with prostate cancer showed that an osteoporosis drug strengthens bones and reduces bone loss.
Researchers at the University at Buffalo have developed a novel drug delivery system using nanocrystals of hydrophobic drugs, which can target tumors with comparable efficacy to conventional surfactant-based systems. The system eliminates the need for separate carriers, reducing toxicity and improving drug penetration.
A study from UNC School of Medicine suggests that improving healthcare access is key to reducing disparities in prostate cancer among black men. The lack of regular healthcare and trust in physicians hindered their ability to receive preventative care, leading to higher death rates.
Researchers at the University of Pennsylvania have discovered a way to pre-screen cancer patients for blood cancer drugs by testing for p53, a tumor-suppressor protein. This test may help identify patients who are most likely to respond to treatment and avoid harmful side effects.
A study published in Cell Press found that the p53 gene, known for preventing cancer, also regulates the suntan response. The researchers discovered that p53 activates the tanning machinery, protecting against sunburns. The findings may lead to new products that produce a tan safely without UV radiation exposure.
Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.
Researchers at the University of Missouri-Columbia have found that a plant extract can be used to stabilize gold nanoparticles, making them nontoxic and stable enough for injection or oral administration. This breakthrough has the potential to revolutionize cancer detection and treatment using nanomedicine.
A recent USC-led study suggests that long-term recreational physical activity plays a protective role against invasive and in situ breast cancer. Women exercising for five or more hours per week experienced a greater decrease in risk of breast cancer compared to less active women.